Abstract
The new compounds TlCuT(IV)Q3 (T=Zr,Hf; Q=S,Se) were prepared by reacting intimate mixtures of Tl2S or TlSe with stoichiometric amounts of the corresponding Group IV metal, Cu and the corresponding chalcogen at 870?C. The four compounds are isostructural and crystallize in Cmcm, Z=4, with a=3.726(4)Ä, b=13.987(9)Ä, c=9.783(4)Ä for TlCuZrS3; a=3.847(1)Ä, b=14.381(6)Ä, c=10.150(1)Ä for TlCuZrSe3; a=3.694(1)Ä, b=14.030(3)Ä, c=9.750(3)Ä for TlCuHfS3; and a=3.831(1)Ä, b=14.409(9)Ä, c=10.124(2)Ä for TlCuHfSe3. Their crystal structures were determined from single crystal diffractometer data (MoK alpha radiation, ambient temperature) and refined to conventional R values of 0.016, 0.040, 0.019 and 0.031 respectively.
An outstanding feature of their crystal structures is the formation of infinite anionic layers, 2-oo-[CuT(IV)Q3]- parallel to (010), which are separated by Tl(+) cations. These layers are built up by edge sharing TQ6 octahedra and distorted CuQ4 tetrahedra.
Average T-Q distances are `d(Zr-S)=2.586(1)Ä, `d(Zr-Se)=2.707(1)Ä, `d(Hf-S)=2.569(2)Ä and `d(Hf-Se)=2.694(1)Ä.
Cu-chalcogen distances are `d(Cu-S)=2.318(2)Ä and `d(Cu-Se)=2.432(3)Ä respectively. The thallium ions are in bicapped trigonal prismatic chalcogen coordinations. The atomic arrangement corresponds to that of KCuZrS3; based on the thallium-chalcogen partial structure it can be regarded as a filled variant of an anti-Re3B structure type.
| Original language | English |
|---|---|
| Number of pages | 5 |
| Journal | Journal of Alloys and Compounds |
| Publication status | Published - 1996 |
Fields of science
- 103040 Photonics
- 104 Chemistry
- 104003 Inorganic chemistry
- 104008 Catalysis
- 104011 Materials chemistry
- 104015 Organic chemistry
- 104016 Photochemistry
- 104021 Structural chemistry
- 106 Biology
- 106002 Biochemistry
- 106032 Photobiology
- 107002 Bionics
- 209001 Biocatalysis
- 209004 Enzyme technology
- 210002 Nanobiotechnology
- 210005 Nanophotonics
- 211908 Energy research
- 211915 Solar technology
- 301114 Cell biology
- 301305 Medical chemistry
- 301904 Cancer research